Bengaluru-based deep-tech neuroscience startup BrainSight AI has successfully raised $5 million in a pre-Series A funding round. The investment was led by IAN Alpha Fund, with participation from IvyCap Ventures, Silver Needle, and existing investors. This fresh funding follows an earlier investment of $925K from Pfizer and others, further boosting the company’s momentum.

BrainSight AI plans to use the newly acquired funds to expand its presence within India, focusing on Tier I and Tier II cities, while also venturing into international markets such as Africa, Southeast Asia, and the US. Additionally, the startup aims to enhance its research and development (R&D) capabilities to further strengthen its product offerings.

Founded in 2019 by Laina Emmanuel and Rimjhim Agrawal, BrainSight AI combines cutting-edge artificial intelligence with neuroscience to provide greater precision in the diagnosis and treatment planning of neuro-oncological and neuropsychiatric disorders. The platform is designed to aid in neurological and psychiatric investigations, significantly improving patient outcomes.

BrainSight’s product suite includes Voxelbox, a machine-learning-powered fMRI processing engine that offers clinicians access to valuable insights, and Snowdrop, a patient care app that ensures treatment compliance and facilitates the building of comprehensive patient profiles.

Currently, BrainSight AI collaborates with over 40 leading hospitals in India, focusing on neurosurgery and radiology departments, particularly for brain tumor cases. The company is now expanding its solutions to address a broader range of neurological and psychiatric conditions, aiming to create a more holistic approach to brain care.

By mapping the brain’s macro-scale neural connections, BrainSight AI is pioneering innovative methods for understanding how the brain’s physiology relates to its functions, ultimately enabling precise diagnoses and prognoses for patients dealing with complex brain-related disorders.